4.1 Closure and visual improvement rates according to
treatment
Transcatheter closure of VSD was first described by
Lock[21] in 1988. In the last four decades, TCC
for PIVSD has justified a feasible and less invasive procedure. Our
results show that the
successful
device implantation rate was 89.7% (95%CI: 0.772- 1.021). The
30- day mortality rate was approximately 31.5% (95%CI of
0.149- 0. 482) and as high as 25.3% (95%CI: 0.072-0.434)
when primary closure at the acute phase (<2 weeks). It is comparatively
lower than the surgical repair treatment within three weeks and more
prolonged than three weeks ,respectively 50% and
38%[22-23]. Data from several sources have
identified the patients who underwent successful percutaneous closure
showed a trend toward a satisfactory long-term
outcome[24-25].
In the comparison of TCC to surgical closure, the pooled analysis of two
studies showed no significant difference in 30-day mortality, immediate
shunt reduction. The small number of studies limits these conclusions.
It is of necessity for future randomized controlled trials to
demonstrate TCC compared with surgical closure.